Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
immunotherapy |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
unresectable hepatocellular carcinoma
|
| gptkbp:ATCCode |
L01FX18
|
| gptkbp:CASNumber |
946414-94-4
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:combinationTherapy |
gptkb:Durvalumab
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:hasMolecularFormula |
C6428H9954N1714O2016S46
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tremelimumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
immunotherapy
|
| gptkbp:otherName |
gptkb:CP-675,206
gptkb:ticilimumab |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue pruritus rash |
| gptkbp:target |
gptkb:CTLA-4
|
| gptkbp:UNII |
4Y2F4KQ39V
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|